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Leber hereditary optic neuropathy (LHON) is a genetic disorder primarily due to mutations of mitochondrial DNA (mtDNA).
Environmental factors are thought to precipitate the visual failure and explain the marked incomplete penetrance of LHON, but
previous small studies have failed to conﬁrm this to be the case. LHON has no treatment, so identifying environmental triggers
is the key to disease prevention, whilst potentially revealing new mechanisms amenable to therapeutic manipulation. To address
this issue, we conducted a large, multicentre epidemiological study of 196 affected and 206 unaffected carriers from 125 LHON
pedigrees known to harbour one of the three primary pathogenic mtDNA mutations: m.3460G4A, m.11778G4A and
m.14484T4C. A comprehensive history of exposure to smoking, alcohol and other putative environmental insults was collected
using a structured questionnaire. We identiﬁed a strong and consistent association between visual loss and smoking, indepen-
dent of gender and alcohol intake, leading to a clinical penetrance of 93% in men who smoked. There was a trend towards
increased visual failure with alcohol, but only with a heavy intake. Based on these ﬁndings, asymptomatic carriers of a
LHON mtDNA mutation should be strongly advised not to smoke and to moderate their alcohol intake.
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Introduction
Leber hereditary optic neuropathy (LHON, MIM 535000) is a
mitochondrial genetic disease that preferentially affects young
adults in their second and third decades of life, with over 95%
of cases arising due to one of three point mutations in the mito-
chondrial genome: m.3460G4A, m.11778G4A and m.14484T4C
(Harding et al., 1995; Mackey et al., 1996; Man et al., 2002;
Newman and Biousse, 2004; Yu-Wai-Man et al., 2009). LHON
is a common cause of inherited visual failure, with a minimum
prevalence of 1 in 30 000 in Northern Europe, and with an
estimated mutation carrier rate of  1 in 350 (Man et al., 2003;
Spruijt et al., 2006; Elliott et al., 2008). Clinically, LHON is
characterized by bilateral sub-acute loss of central vision as a
result of focal degeneration of the retinal ganglion cell layer
within the papillomacular bundle (Yu-Wai-Man et al., 2009).
The visual prognosis is poor and the majority of patients
remain severely visually impaired secondary to the marked
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ﬁelds.
LHON shows marked incomplete penetrance with only  50%
of male and  10% of female carriers developing the optic neuro-
pathy in their lifetime (Seedorff, 1985; Brown and Wallace, 1994;
Nikoskelainen, 1994). The secondary factors modulating the mito-
chondrial DNA (mtDNA) LHON mutations still remain largely
undeﬁned, although the gender bias has been linked to the
synergistic inﬂuence of visual-loss susceptibility loci on the
X-chromosome (Hudson et al., 2005; Shankar et al., 2008).
Genetic factors, however, cannot provide a complete explanation
for the reduced penetrance. Five pairs of monozygotic twins with
a primary LHON mutation have been identiﬁed in the literature
(Nikoskelainen et al., 1987; Newman et al., 1991; Johns et al.,
1993; Harding et al., 1995; Biousse et al., 1997; Lam, 1998) and
among two pairs, one sibling has remained visually unaffected on
long-term follow-up (Johns et al., 1993; Biousse et al., 1997).
Whilst it is possible that the unaffected sibling will lose vision
in later life, this discordance supports the role of environmental
factors in triggering visual loss among at-risk carriers. LHON is
therefore likely to be a complex multifactorial disease, with
environmental triggers operating at the individual level con-
tributing to the observed intra- and inter-familial variability in
penetrance.
A limited number of relatively small case–control studies have
attempted to address this important issue, some of which suggest
an increased risk of visual loss among LHON carriers with high
alcohol and tobacco consumption (Cullom et al., 1993; Golnik and
Shaible, 1994; Riordan-Eva et al., 1995; Chalmers and Harding,
1996; Tsao et al., 1999; Sadun et al., 2003). However, the largest
study to date involving affected and unaffected siblings from
80 LHON sibships found no relationship between smoking or alco-
hol and the likelihood of visual failure (Kerrison et al., 2000).
There are also anecdotal reports of trauma, nutritional deprivation,
metabolic disturbance, exposure to industrial toxins, anti-retroviral
drugs, psychological stress or acute illness precipitating the onset
of blindness in LHON, but the strength of the causal relationship is
difﬁcult to establish (DuBios and Feldon, 1992; Johns et al., 1993;
Hwang and Park, 1996; Mackey et al., 2003; Sadun et al., 2003;
Sanchez et al., 2006; Carelli et al., 2007).
There is currently no proven treatment in LHON that will either
prevent disease conversion or improve visual prognosis following
the onset of optic neuropathy. The identiﬁcation of potentially
modiﬁable risk factors would therefore contribute signiﬁcantly to
counselling these families, and reveal potential disease mechan-
isms. To address this issue we carried out the largest multi-
centre study of potential environmental triggers in 402 LHON
mtDNA mutation carriers.
Subjects and Methods
Subjects
A structured questionnaire was conducted on 196 affected and
206 unaffected carriers (n=402) from 125 genealogically distinct
LHON pedigrees in three centres: Newcastle, UK (n=47);
Rotterdam, the Netherlands (n=46); and Munich, Germany (n=32).
All LHON carriers were homoplasmic for one of the three primary
mtDNA mutations: m.3460G4A( n=71), m.11778G4A( n=270) and
m.14484T4C( n=61), conﬁrmed by mtDNA sequencing, restriction
fragment length polymorphism analysis or primer extension assay.
With the exception of one Asian individual, all participants were of
white Caucasian origin. As well as having ethical approval, this study
complied with the Declaration of Helsinki.
Data collection
Participants were interviewed via telephone by three investigators
(MAK, AK and ML) using a standardized questionnaire that has
been adapted from previous studies (Tsao et al., 1999; Kerrison
et al., 2000) (Supplementary data). The dataset collected included
basic demographic details, affected status, age of onset (time at
which ﬁrst symptoms were noted), time course and progression of
visual loss, and a detailed account of exposure to possible environ-
mental triggers to allow a quantitative analysis where applicable.
The lifestyle factors speciﬁcally queried were (i) smoking, (ii) alcohol,
(iii) trauma, (iv) recreational drugs, (v) occupational and industrial toxin
exposure, (vi) diet, (vii) physical exercise, (viii) medication history
including vitamins and herbal remedies and (ix) any relevant medical
comorbidity. Consumption of alcoholic beverages (beer, wine, liquor
and alcopops) among subjects was combined and converted to
standardized units of alcohol as outlined by the UK Ofﬁce for
National Statistics (Ofﬁce for National Statistics, 2007). Cumulative
consumption of alcohol was measured as ‘drink years’, which was
calculated by the units of alcohol per week multiplied by the
number of years of drinking, taking into account the variations in
levels of consumption as identiﬁed through the questionnaire.
Maximum intensity of alcohol consumption was quantiﬁed as the
maximum units of alcohol consumed in a single week. In line with a
previous study (Kerrison et al., 2000), cumulative consumption and
maximum intensity were analysed as both continuous variables and
categorical variables by creating three subject groups: (i) non-drinkers,
(ii) those drinking 575th percentile (light drinking) and (iii) those
drinking 575th percentile (heavy drinking), using the level of alcohol
consumption among unaffected LHON carriers to deﬁne the reference
percentile ranges. Affected LHON carriers who only began drinking
after losing vision had an alcohol exposure of zero and for those
who started drinking beforehand, only their consumption (cumulative
and maximum intensity) up to the onset of visual loss was considered
for the purposes of statistical analysis. A similar analysis protocol was
applied to smoking, with cumulative smoking expressed in terms
of ‘pack years’, calculated by multiplying the number of packs of
cigarettes smoked per day by the number of years of smoking, and
maximum intensity of smoking quantiﬁed in terms of the maximum
number of cigarettes consumed in a single day.
Statistical analysis
Statistical analyses were performed using SPSS
TM v.15 statistical
software (Chicago, IL, USA). Survival analysis was carried out by
constructing Kaplan–Meier survival curves plotted against age,
gender and the speciﬁc LHON mutation and including censored
cases i.e. unaffected individuals who, at the time of interview, had
not lost vision. Binary logistic regression was used to determine
which variables in our dataset inﬂuenced the risk of visual loss
among LHON carriers. This form of analysis assumes that the
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variables included in the model:
Log
P
1   P

¼ B0 þ B1X1 þ B2X2 þ ...BnXn
where P is the probability of a LHON carrier converting to affected
disease status; X1, X2...Xn represent the chosen predictor variables;
and B0, B1,...Bn are coefﬁcients reﬂecting the nature of each predic-
tor (Bland, 2000). Visual failure was the dependent response variable
used in the model, with the following as independent variables: (i) age,
(ii) gender, (iii) LHON mutation (m.11778G4A, m.3460G4A,
m.14484T4C), (iv) cumulative consumption of tobacco and alcohol
and (v) maximum intensity of tobacco and alcohol consumption.
Categorical smoking and alcohol data incorporated into the model
was based on the 75th percentiles for the unaffected LHON carrier
group.
Results
The mean age at onset of visual loss in the affected individuals
was 27.9 years (SD=14.9), with a mean disease duration of 15.5
years (SD=15.4) (Table 1). In a minority of affected carriers, visual
failure occurred before the age of 10 years (n=15, 7.7%) and
after the age of 50 years (n=18, 9.2%). There was no difference
in the age of onset of visual loss among the three primary LHON
mutations (Kaplan–Meier, log rank P=0.946) (Fig. 1). Among the
affected group, 74.5% were male, with a male to female ratio of
2.9:1 and male gender was a signiﬁcant risk factor for visual
loss [Odds ratio (OR)=7.11, 95% conﬁdence interval
(CI)=4.58–11.03, P50.001] (Fig. 2).
Approximately two-thirds of affected individuals were smokers,
compared with approximately half of the unaffected LHON
carriers (Tables 1 and 2). There was no signiﬁcant difference in
mean cumulative tobacco consumption between affected and
unaffected LHON carriers (6.57 pack years, SD=12.37 versus
7.25 pack years, SD=11.30, P=0.57), but mean maximum
intensity of smoking was signiﬁcantly higher among affected
individuals (16.66 cigarettes per day, SD=19.62 versus 11.55
cigarettes per day, SD=14.97, P50.001).
The majority of study subjects drank alcohol (94.4% of the
affected individuals and 91.2% of the unaffected individuals,
Tables 1 and 3). Mean cumulative alcohol consumption among
Table 1 Characteristics of the study population
Affected Unaffected
Number of individuals
m.11778G4A (%) 132 (67.3) 138 (67.0)
m.3460G4A (%) 35 (17.9) 36 (17.5)
m.14484T4C (%) 29 (14.8) 32 (15.5)
Total 196 206
Sex, N (%)
Male 146 (74.5) 60 (29.1)
Female 50 (25.5) 146 (70.9)
Male: female ratio 2.9 0.4
Age at time of study (years)
Mean (SD) 43.3 (16.9) 47.8 (14.9)
Range 13–82 14–83
Numbers of tobacco smokers (%)
Male 107 (73.3) 33 (55.0)
Female 27 (54.0) 75 (51.4)
Whole group 134 (68.4) 108 (52.4)
Numbers of alcohol drinkers (%)
Male 139 (95.2) 57 (95.0)
Female 46 (92.0) 131 (89.7)
Whole group 185 (94.4) 188 (91.3)
Figure 1 Kaplan–Meier curve showing disease onset with regard to the three primary LHON mutations (P=0.946 by log-rank test).
Age of onset (years) was deﬁned as the age when the patients ﬁrst noticed their visual symptoms.
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Table 2 Levels of tobacco consumption among LHON carriers and ORs for vision loss
Affected (%) Unaffected (%) Mean (SD) ORs
a (95% CI) P-value
Cumulative smoking consumption (Pack years)
None 62 (31.6) 98 (47.6) – – –
Light smoking 114 (58.2) 81 (39.3) 5.82 (5.45) 2.23 (1.45–3.41) 50.001
c
Heavy smoking 20 (10.2) 27 (13.1) 32.47 (14.63) 1.17 (0.61–2.27) 0.735
Whole group
b 134 (68.4) 108 (52.4) 11.00 (13.28) 1.96 (1.31–2.95) 0.001
c
Maximum smoking consumption
None 62 (31.6) 98 (47.6) – – –
Light smoking 78 (39.8) 80 (38.8) 12.50 (8.82) 1.54 (0.99–2.41) 0.071
Heavy smoking 56 (28.6) 28 (13.6) 42.32 (12.84) 3.16 (1.82–5.50) 50.001
c
Whole group
b 132 (68.4) 108 (52.4) 22.85 (17.60) 1.96 (1.31–2.95) 0.001
c
The light and heavy smoking subgroups were based on whether the subject was below or above the 75th percentile values derived from the level of smoking
consumption among unaffected LHON carriers.
a Comparison to unaffected LHON carriers who were non-smokers.
b Whole group includes both light and heavy tobacco consumers
c Signiﬁcant at P50.05 level.
Table 3 Levels of alcohol consumption among LHON carriers and ORs for vision loss
Affected (%) Unaffected (%) Mean (SD) OR
a (95% CI) P-value
Cumulative alcohol consumption (Drink years)
None 11 (5.6) 18 (8.8) – – –
Light drinking 137 (69.9) 141 (68.4) 16.10 (16.31) 1.59 (0.72–3.49) 0.329
Heavy drinking 48 (24.5) 47 (22.8) 132.02 (99.93) 1.67 (0.71–3.91) 0.290
Whole group
b 185 (94.4) 188 (91.3) 45.62 (72.66) 1.61 (0.74–3.50) 0.252
Maximum alcohol consumption (Units of alcohol per week)
None 11 (5.6) 18 (8.8) – – –
Light drinking 85 (43.4) 138 (67.0) 8.32 (8.98) 1.01 (0.45–2.24) 1.000
Heavy drinking 100 (51.0) 50 (24.3) 90.95 (110.47) 3.27 (1.44–7.46) 0.006
c
Whole group
b 185 (94.4) 188 (91.3) 41.55 (81.13) 1.61 (0.74–3.50) 0.252
The light and heavy smoking subgroups were based on whether the subject was below or above the 75th percentile values derived from the level of alcohol
consumption among unaffected LHON carriers.
a Comparison to unaffected LHON carriers who were non-drinkers.
b Whole group includes both light and heavy alcohol consumers
c Signiﬁcant at P50.05 level.
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cantly different to unaffected carriers (43.26 drink years,
SD=73.39, P=0.853). However, the mean maximum intensity
of alcohol consumption for the affected group was signiﬁcantly
higher than for the unaffected group (54.43U/week, SD=
104.21 versus 23.78U/week, SD=36.88, P50.001).
Kaplan–Meier survival analysis revealed signiﬁcant relationships
with (i) cumulative smoking, (ii) maximum intensity smoking and
(iii) maximum intensity drinking, but not cumulative drinking
(Figs 3 and 4). These initial results suggested that both smoking
and alcohol consumption increased the risk of visual failure in
LHON pedigrees. However, male carriers drank and smoked
more than female carriers (maximum smoking: P=0.001; cumula-
tive smoking P=0.096; maximum alcohol: P50.001; cumulative
alcohol: P50.001), raising the possibility that the apparent asso-
ciation of visual loss with alcohol and smoking could actually be
secondary to the gender bias in LHON i.e. the greater number of
affected males. To address this issue, binary logistic regression was
performed which allows a more stringent statistical analysis by
simultaneously analysing all the variables that could inﬂuence
the risk of a LHON carrier converting, therefore minimizing the
chance of detecting a spurious statistical association.
With smoking and alcohol consumption treated as cate-
gorical variables in the logistic regression model, both light
Figure 3 Kaplan–Meier curve showing the disease onset according to tobacco consumption. (A) Cumulative smoking (P50.001 by
log-rank test). (B) Maximum intensity smoking (P=0.011 by log-rank test).
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(OR=3.26; 95% CI=1.31–8.07; P=0.011) cumulative smoking
were independent risk factors for visual failure compared with
the non-smoking group, but for maximum smoking intensity,
only heavy smoking (OR=2.80; 95% CI=1.31–5.99; P=0.008)
showed a signiﬁcant association (Table 4). When analysed as
continuous variables, both cumulative (OR=1.04; 95%
CI=1.01–1.06; P=0.004) and maximum intensity (OR=1.02;
95% CI=1.00–1.04; P=0.021) of smoking were signiﬁcantly
associated with increased risk of visual loss (Table 5). Although
there was a trend towards a greater likelihood of conversion
among LHON carriers who were heavy drinkers (575th per-
centile), both cumulative and maximum intensity of alcohol
consumption did not reach statistical signiﬁcance either as
categorical or continuous variables (Tables 4 and 5). There was
also no signiﬁcant statistical interaction between smoking, alcohol
and gender intake when considered as either continuous or
categorical variables. Further evidence that gender and smoking
are independent risk factors for visual failure in LHON was
apparent from Kaplan–Meier survival analysis of male and
female smokers and non-smokers. Clinical penetrance was greater
in male non-smokers than female non-smokers (Fig. 5A,
P50.001). However, the striking effect of smoking in males
was associated with a 93% life-time penetrance of visual failure,
compared with only 66% in non-smoking males and 33% in
smoking females (Fig. 5B, P50.001).
Figure 4 Kaplan–Meier curve showing the disease onset according to alcohol consumption. (A) Cumulative drinking (P=0.108 by
log-rank test). (B) Maximum intensity drinking (P50.001 by log-rank test).
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psychological stress (13.3%, n=26) and physical trauma (5.6%,
n=11), with other subjects reporting a concurrent physical illness
(4.6%, n=9), poor nutrition (0.5%, n=1) and chemotherapy
(0.5%, n=1) as signiﬁcant personal events prior to the onset
of symptoms. The nature of the physical trauma included head
injury (n=7), road trafﬁc accident (n=3) and limb injury (n=1).
A proportion of affected LHON carriers (33.7%, n=66) also
reported occupational or accidental toxin exposure in the immedi-
ate period preceding visual loss, which included exhaust fumes
(n=16), dry cleaning solvents (n=13), asbestos (n=5), lead
(n=4), scrap metals (n=4) and ﬁbreglass (n=2), at high levels
not encountered in a normal environment. There was no signiﬁ-
cant difference between affected and unaffected LHON carriers in
their diet, level of physical exercise, recreational drugs, medication
history or medical comorbidity.
Discussion
The evidence supporting the role of environmental risk factors in
precipitating the optic neuropathy in LHON has so far been largely
based on anecdotal reports (DuBios and Feldon, 1992; Golnik and
Shaible, 1994; Rizzo, 1995; Hwang and Park, 1996; Mackey et al.,
2003; Sanchez et al., 2006; Carelli et al., 2007) and small case
series (Newman et al., 1991; Cullom et al., 1993; Riordan-Eva
et al., 1995). Larger studies speciﬁcally investigating the role of
tobacco and alcohol have produced conﬂicting results (Chalmers
and Harding, 1996; Tsao et al., 1999; Kerrison et al., 2000;
Sadun et al., 2003) (Table 6). Two separate studies of large
m.11778G4A LHON pedigrees did suggest an important role for
smoking in disease conversion (Tsao et al., 1999; Sadun et al.,
2003), but crucially, only one study (Kerrison et al., 2000) consid-
ered exposure levels before the onset of visual loss. By carrying
out the largest study to date, and controlling for the major factors
known to inﬂuence disease penetrance, we have provided strong
evidence that smoking is associated with an increased risk of visual
failure among LHON carriers. For both cumulative and maximum
intensity levels, heavy smokers were also more likely to
be affected than light smokers, providing further support for a
biologically plausible dose–response relationship.
Our LHON cohort is comparable with other published epide-
miological case series, with a predominance of the m.11778G4A
mutation, most patients becoming affected in their twenties,
and males having a higher risk of visual loss than female carriers.
The gender bias was slightly lower than the ﬁgures reported in
previous LHON case series, where males were on average ﬁve
times more likely to be affected than female carriers (Man
et al., 2002; Yu-Wai-Man, 2009). Although this discrepancy can
be accounted for by the recruitment of a proportionally larger
number of affected female carriers, this ascertainment bias is
unlikely to affect the general applicability of our ﬁndings.
Initial analysis of our dataset indicated an increased risk of
disease conversion among LHON carriers who were heavy drin-
kers. However, after controlling for possible confounding variables
such as age, gender and the primary LHON mutations using a
logistic regression model, both cumulative and maximum intensity
of alcohol failed to reach statistical signiﬁcance. The trend towards
a signiﬁcant relationship between visual loss and heavy alcohol
intake suggests a weaker causal relationship between levels of
alcohol consumption and visual failure, but this cannot be sub-
stantiated at present. Although we aimed to investigate the role
of other environmental triggers in LHON, besides smoking and
alcohol, and about a third of our patients reported possible insults
prior to the onset of visual loss, the retrospective nature of
our study made it difﬁcult to draw any ﬁrm conclusions regarding
their actual relevance.
What pathophysiological mechanisms could explain the
increased susceptibility to optic neuropathy among smoking
LHON carriers? Oxidative phosphorylation (OXPHOS) produces
most of the adenosine triphosphate (ATP) requirements and this
process is achieved by a chain of ﬁve respiratory complexes (I–V)
along the inner mitochondrial membrane. All three primary LHON
mutations result in amino acid substitutions within subunits that
Table 4 Binary logistic regression models for the prediction of vision loss: categorical consumption levels of tobacco
and alcohol
Model 1 (cumulative) Model 2 (maximum)
Predictor variables ORs (95% CI) P-value ORs (95% CI) P-value
Light smoking
a 1.93 (1.08–3.46) 0.027
c 1.63 (0.88–3.02) 0.118
Heavy smoking
a 3.26 (1.31–8.07) 0.011
c 2.80 (1.31–5.99) 0.008
c
Light drinking
b 1.52 (0.50–4.64) 0.459 1.32 (0.44–3.98) 0.625
Heavy drinking
b 2.75 (0.76–10.02) 0.125 2.31 (0.73–7.30) 0.154
a Comparison with non-smokers.
b Comparison with non-drinkers
c Signiﬁcant at P50.05 level. Both models also incorporated the following variables: age, gender and LHON mutation.
Table 5 Binary logistic regression models for the
prediction of vision loss: continuous consumption levels
of tobacco and alcohol
Predictor
Model 3 (cumulative) Model 4 (maximum)
variables ORs (95% CI) P-value ORs (95% CI) P-value
Smoking 1.04 (1.01–1.06) 0.004
a 1.02 (1.00–1.04) 0.021
a
Alcohol 1.00 (1.00–1.01) 0.093 1.00 (1.00–1.01) 0.176
a Signiﬁcant at P50.05 level. Both models also incorporated the following
variables: age, gender and LHON mutation.
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assays used, a mild to moderate reduction in respiratory chain
activity has been identiﬁed (Yu-Wai-Man et al., 2009). Cigarette
smoking could potentiate this energy deﬁcit by either compromis-
ing complex I activity directly (Smith et al., 1993, 1994), or limit-
ing OXPHOS through elevated carboxyhaemoglobin levels and
a reduction in arterial oxygen content (Gvozdjak et al., 1987;
van Jaarsveld et al., 1992). In a study, cytochrome c oxidase
(COX, complex IV) activity in rats was reduced by 25% after
30min exposure to cigarette smoke, and prolonged exposure
resulted in further decreases in COX activity (Gvozdjak et al.,
1987). This led to an increase in reactive oxygen species, which
have been implicated as potent triggers of apoptosis and retinal
ganglion cell loss in LHON (Yu-Wai-Man et al., 2009). There is
also a suggestion that secondary mtDNA abnormalities are more
prevalent among smokers, with an increased rate of somatic
mtDNA mutations and a compensatory increase in mtDNA copy
number (Tan et al., 2008). These ﬁndings are consistent with a
deleterious effect of smoking on mitochondrial biogenesis, which
potentially could further exacerbate the pre-existing LHON-
induced complex I defect in retinal ganglion cells, precipitating
the onset of optic nerve dysfunction.
Figure 5 Kaplan–Meier curve showing the disease onset according to gender and smoking status. (A) Non-smoking individuals
(P50.001 by log-rank test). (B) Smoking individuals (P50.001 by log-rank test).
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age of 10 years, none of whom had consumed tobacco or alcohol
prior to visual loss, and there was not an increased rate of smoking
among close family members compared with the rest of the
affected group. This is in keeping with the prevailing view that
LHON is a multifactorial disease, and the visual failure is likely due
to a complex interaction between genetic and environmental fac-
tors, with smoking as only one of the susceptibility factors.
Although we applied a stringent logistic regression model to
reduce the risk of ﬁnding a spurious association, the nature
of our study did not allow us to control for the inﬂuence of
mtDNA haplogroups (Hudson et al., 2007) and the presence or
absence of the high-risk haplotype at Xp21 which has been shown
to increase the risk of visual failure  35-fold for the m.11778G4A
and m.14484T4C mutations but not for m.3460G4A (Hudson
et al., 2005). However, our results clearly indicate that future
association studies of possible nuclear modiﬁer genes in LHON
should ideally control for the level of smoking and alcohol con-
sumption in any analyses performed. Being a retrospective study
based upon telephone interviews, our study was also potentially
subject to recall bias, with patients reporting information about
their alcohol and smoking history over a time period sometimes
spanning several decades.
Our large multi-centre study of 125 LHON pedigrees has
revealed an important and consistent role for smoking in increas-
ing disease penetrance among carriers of the three primary
mtDNA mutations. Perhaps the most striking ﬁnding is that 93%
of men who smoke develop visual failure if they harbour the
LHON mtDNA mutation. The effect of smoking is also apparent
in women, albeit with a reduced overall clinical penetrance due to
the gender bias. These ﬁndings have important practical implica-
tions for genetic counselling and LHON carriers should be strongly
advised not to smoke. Although the association between visual
failure and heavy alcohol consumption was not statistically signif-
icant in the logistic regression analysis, it would also seem sensible
for LHON mutation carriers to moderate their alcohol intake and
avoid binge drinking episodes.
Supplementary material
Supplementary material is available at Brain online.
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